TNFRSF17

Across TCGA pan-cancer cohorts, TNFRSF17 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TNFRSF17 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TNFRSF17 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TNFRSF17 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LSCC, LUAD, and CCRCC are the cancer types where TNFRSF17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	0.505	0.947	.002	38	view →
LUAD	OS	Median	All	1.000	0.564	.003	18	view →
CCRCC	OS	Median	All	0.675	1.000	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TNFRSF17–LSCC (OS)

Open the LSCC breakdown →